# Title

 Food and Drugs. PART 606â€”CURRENT GOOD MANUFACTURING PRACTICE FOR BLOOD AND BLOOD COMPONENTS


# ID

 CFR-2018-title21-vol7.Pt. 606


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                   |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'prior to', 'more than', 'not to exceed', 'maximum', 'less than', 'after', 'minimum', 'no less than', 'at least', 'no more than']                                   |
| Duration    | ['15.0 minute', '4.0 hour', '6.0 hour', '2.0 hour', '72.0 hour', '6.0 month', '3.0 day', '45.0 day', '7.0 day', '3.0 month', '8.0 week', '10.0 year', '20.0 minute']                     |
| Condition   | ['unless', 'not subject to', 'where', 'as soon as', 'subject to', 'when', 'if']                                                                                                          |
| Entities    | ['Adverse', 'Careful', 'Plasma', 'Such', 'Equipment', 'Food', 'Contains', 'Research', 'Remain', 'Good', 'Distribution', 'Laboratory', 'Plateletpheresis', 'Products Subject', 'License'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                             |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------|
| at least      | plasma is separated from the formed elements and at least the red blood cells are returned to the                                   |
| after         | (i) Processing means any procedure employed  after  collection, and before or                                                       |
| before        | Processing means any procedure employed after collection, and before or after compatibility testing of blood, and includes          |
| after         | (i) Processing means any procedure employed  after  collection, and before or                                                       |
| prior to      | (5) The storage of finished products  prior to  distribution.                                                                       |
| at least      | that shall be observed, standardized and calibrated with at least the following frequency, include but are not limited              |
| no less than  | The effectiveness of the sterilization procedure shall be  no less than that achieved by an attained temperature of 121.5           |
| prior to      | examined visually for damage or evidence of contamination prior to  its use and immediately after filling.                          |
| after         | of contamination prior to its use and immediately after  filling.                                                                   |
| after         | container shall not be used, or, if detected after  filling, shall be properly discarded.                                           |
| minimum       | of performing donor qualifying tests and measurements, including minimum and maximum values for a test or procedure                 |
| maximum       | donor qualifying tests and measurements, including minimum and maximum values for a test or procedure when a                        |
| maximum       | to prepare the site of phlebotomy to give maximum  assurance of a sterile container of blood.                                       |
| before        | maintained pursuant to these regulations shall be reviewed before the release or distribution of a lot or                           |
| after         | may be performed at appropriate periods during or after  blood collecting, processing, compatibility testing and storing.           |
| at least      | as such specific procedures are consistent with, and at least as stringent as, the requirements contained in this                   |
| after         | to identify accurately the contents of a container after  blood components considered finished products have been prepared.         |
| within        | Cells, the volume of the product, accurate to within &#177;10 percent; or optionally for Platelets, the volume                      |
| within        | Cells, the volume of the product, accurate to within &#177;10 percent; or optionally for Platelets, the volume                      |
| within        | convertible to cash, do not constitute monetary payment within  the meaning of this paragraph.                                      |
| prior to      | blood and blood components shipped in an emergency prior to completion of required tests, in accordance with &#167;&#8201;610.40(g) |
| before        | and 640.5(b) or (c) of this chapter completed before  shipment.                                                                     |
| before        | 640.5(b) or (c) of this chapter not completed before  shipment.                                                                     |
| before        | following information: (a) Instructions to mix the product before  use.                                                             |
| more than     | begin administration as soon as possible, but not more than  4 hours after entering the container.                                  |
| after         | as possible, but not more than 4 hours after  entering the container.                                                               |
| within        | applicable, instructions to begin administration of the product within  a specified time after thawing.                             |
| after         | administration of the product within a specified time after  thawing.                                                               |
| at least      | (2) The statement: &#8220;Usually contains  at least 150 milligrams of fibrinogen&#8221;; or, alternatively, the average            |
| no more than  | (4) Instructions to thaw the product for  no more than 15 minutes at a temperature of between 30                                    |
| after         | (5) Instructions to store at room temperature  after thawing and to begin administration as soon as                                 |
| no more than  | to begin administration as soon as possible but no more than 4 hours after entering the container or after                          |
| after         | (5) Instructions to store at room temperature  after thawing and to begin administration as soon as                                 |
| after         | (5) Instructions to store at room temperature  after thawing and to begin administration as soon as                                 |
| within        | after entering the container or after pooling and within  6 hours after thawing.                                                    |
| after         | (5) Instructions to store at room temperature  after thawing and to begin administration as soon as                                 |
| less than     | use of fresh recipient serum or plasma samples less than 3 days old for all pretransfusion testing if                               |
| within        | if the recipient has been pregnant or transfused within  the previous 3 months.                                                     |
| within        | of donation where the donor may be contacted within  8 weeks after donation.                                                        |
| after         | the donor may be contacted within 8 weeks after  donation.                                                                          |
| before        | and red blood cells during storage and immediately before  distribution.                                                            |
| before        | of blood, including signature of requesting physician obtained before  or after release.                                            |
| after         | including signature of requesting physician obtained before or after  release.                                                      |
| within        | records: (i) Sterilization of supplies and reagents prepared within the facility, including date, time interval, temperature and    |
| no less than  | You must retain individual product records  no less than 10 years after the records of processing are                               |
| after         | individual product records no less than 10 years after the records of processing are completed or 6                                 |
| after         | individual product records no less than 10 years after the records of processing are completed or 6                                 |
| at least      | paragraph (e)(2) of this section must be updated at least monthly to add donors newly deferred under &#167;&#8201;610.41            |
| within        | (for mailing address, see &#167;&#8201;600.2(a) of this chapter), within 7 days after the fatality by the collecting                |
| after         | see &#167;&#8201;600.2(a) of this chapter), within 7 days after the fatality by the collecting facility in the                      |
| not to exceed | possible but you must report at a date not to exceed 45-calendar days from the date you, your agent,                                |


## Duration

| Duration    | Context                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20.0 minute | The effectiveness of the sterilization procedure shall be no less than that achieved by an attained temperature of 121.5 &#176;C (251 &#176;F) maintained for 20 minutes by saturated steam or by an attained temperature of 170 &#176;C (338 &#176;F) maintained for 2 hours with dry heat.                                                                                                                                                        |
| 2.0 hour    | The effectiveness of the sterilization procedure shall be no less than that achieved by an attained temperature of 121.5 &#176;C (251 &#176;F) maintained for 20 minutes by saturated steam or by an attained temperature of 170 &#176;C (338 &#176;F) maintained for 2 hours with dry heat.                                                                                                                                                        |
| 72.0 hour   | (4)(i) The expiration date, including the day, month, and year, and, if the dating period for the product is 72 hours or less, including any product prepared in a system that might compromise sterility, the hour of expiration.                                                                                                                                                                                                                  |
| 4.0 hour    | (2) Instructions to begin administration as soon as possible, but not more than 4 hours after entering the container.                                                                                                                                                                                                                                                                                                                               |
| 15.0 minute | (4) Instructions to thaw the product for no more than 15 minutes at a temperature of between 30 and 37 &#176;C.                                                                                                                                                                                                                                                                                                                                     |
| 4.0 hour    | (5) Instructions to store at room temperature after thawing and to begin administration as soon as possible but no more than 4 hours after entering the container or after pooling and within 6 hours after thawing.                                                                                                                                                                                                                                |
| 6.0 hour    | (5) Instructions to store at room temperature after thawing and to begin administration as soon as possible but no more than 4 hours after entering the container or after pooling and within 6 hours after thawing.                                                                                                                                                                                                                                |
| 3.0 day     | (b) The use of fresh recipient serum or plasma samples less than 3 days old for all pretransfusion testing if the recipient has been pregnant or transfused within the previous 3 months.                                                                                                                                                                                                                                                           |
| 3.0 month   | (b) The use of fresh recipient serum or plasma samples less than 3 days old for all pretransfusion testing if the recipient has been pregnant or transfused within the previous 3 months.                                                                                                                                                                                                                                                           |
| 8.0 week    | (ix) The donor's postal address provided at the time of donation where the donor may be contacted within 8 weeks after donation.                                                                                                                                                                                                                                                                                                                    |
| 10.0 year   | You must retain individual product records no less than 10 years after the records of processing are completed or 6 months after the latest expiration date for the individual product, whichever is the later date.                                                                                                                                                                                                                                |
| 6.0 month   | You must retain individual product records no less than 10 years after the records of processing are completed or 6 months after the latest expiration date for the individual product, whichever is the later date.                                                                                                                                                                                                                                |
| 7.0 day     | A written report of the investigation must be submitted to the Director, Office of Compliance and Biologics Quality, CBER, by mail, facsimile, or electronically transmitted mail (for mailing address, see &#167;&#8201;600.2(a) of this chapter), within 7 days after the fatality by the collecting facility in the event of a donor reaction, or by the facility that performed the compatibility tests in the event of a transfusion reaction. |
| 45.0 day    | You should report a biological product deviation as soon as possible but you must report at a date not to exceed 45-calendar days from the date you, your agent, or another person who performs a manufacturing, holding, or distribution step under your control, acquire information reasonably suggesting that a reportable event has occurred.                                                                                                  |


## Condition

| Condition      | Context                                                                                                                                     |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------------|
| where          | of the products shall be excluded from areas where the collection, processing, compatibility testing, storage or distribution               |
| when           | shall: (a) Provide adequate space for the following when applicable: (1) Private and accurate examinations of individuals                   |
| where          | Drains shall be of adequate size and,  where connected directly to a sewer, shall be equipped                                               |
| if             | Each blood collecting container and its satellite container(s), if any, shall be examined visually for damage or                            |
| when           | examination shall include inspection for breakage of seals, when  indicated, and abnormal discoloration.                                    |
| if             | observed, the container shall not be used, or, if  detected after filling, shall be properly discarded.                                     |
| not subject to | Evaluation and Research, are not applicable to establishments not subject to licensure under section 351 of the Public Health               |
| where          | to the personnel for use in the areas where  the procedures are performed.                                                                  |
| when           | are not limited to, descriptions of the following, when applicable: (1) Criteria used to determine donor eligibility,                       |
| when           | and maximum values for a test or procedure when  a factor in determining acceptability.                                                     |
| where          | (8) Pretransfusion testing,  where applicable, including precautions to be taken to identify                                                |
| if             | (11) Length of expiration dates,  if any, assigned for all final products as prescribed                                                     |
| if             | (17) Procedures of plasmapheresis, plateletpheresis, and leukapheresis,  if performed, including precautions to be taken to ensure          |
| if             | (18) Procedures for preparing recovered plasma,  if performed, including details of separation, pooling, labeling, storage,                 |
| when           | (HIV) infection or hepatitis C virus (HCV) infection when  tested under &#167;&#8201;610.40 of this chapter, or                             |
| when           | (HIV) infection or hepatitis C virus (HCV) infection when  tested under &#167;&#8201;610.40 of this chapter, or                             |
| if             | (21) Procedures for donor not if ication and not                                                                                            |
| subject to     | (3) Other organizations or individual blood banks,  subject to approval by the Director, Center for Biologics Evaluation                    |
| if             | (2) The name, address, unique facility ident if ier, and,                                                                                   |
| if             | date, including the day, month, and year, and, if the dating period for the product is 72                                                   |
| if             | collection date for each unit in the pool. if                                                                                               |
| where          | applicable, the name and volume of source material. where                                                                                   |
| if             | cautions, and methods of infusion.&#8221; (iii) &#8220;Properly ident if y intended recipient.&#8221; (iv) &#8220;This product may transmit |
| if             | type of the donor must be designated conspicuously. if                                                                                      |
| if             | positive, the product must be labeled: &#8220;Rh positive.&#8221; if                                                                        |
| if             | positive, the product must be labeled: &#8220;Rh positive.&#8221; if                                                                        |
| if             | Director, Center for Biologics Evaluation and Research (CBER). if                                                                           |
| if             | Director, Center for Biologics Evaluation and Research (CBER). if                                                                           |
| if             | serological syphilis testing under &#167;&#8201;640.65(b) of this chapter. if                                                               |
| when           | labeled in accordance with &#167;&#8201;610.40 of this chapter, when the donation is tested and demonstrates evidence of                    |
| subject to     | (i) Who is  subject to  this machine-readable requirement?                                                                                  |
| subject to     | (ii) What blood products are  subject to  this machine-readable requirement?                                                                |
| subject to     | blood and blood components intended for transfusion are subject to  the machine-readable information label requirement in this section.     |
| where          | (v) Where does the machine-readable information go? where                                                                                   |
| unless         | solid black or other solid color for ABO. unless                                                                                            |
| if             | must include: (i) The type of anticoagulant, and if applicable, the volume of Whole Blood and type                                          |
| if             | must include: (i) The type of anticoagulant, and if applicable, the volume of Whole Blood and type                                          |
| if             | collection of the oldest material in the container. if                                                                                      |
| if             | collection of the oldest material in the container. if                                                                                      |
| subject to     | of anticoagulant with which the product was prepared. subject to                                                                            |
| where          | &#8220;Store at &#8722;20 &#176;C or colder,&#8221; provided, that where plasma is intended for manufacturing into noninjectable products,  |
| when           | control reagents for the serologic test for syphilis. when                                                                                  |
| if             | circular of information must be available for distribution if  the product is intended for transfusion.                                     |
| when           | was prepared from blood that was found negative when tested for relevant transfusion-transmitted infections, as required under              |
| when           | The names and results of all tests performed when  necessary for safe and effective use.                                                    |
| if             | Instructions to administer a suitable plasma volume expander if Red Blood Cells are substituted when Whole Blood                            |
| when           | volume expander if Red Blood Cells are substituted when  Whole Blood is the indicated product.                                              |
| as soon as     | (2) Instructions to begin administration  as soon as possible, but not more than 4 hours after                                              |
| if             | warning against further processing of the frozen product if  there is evidence of breakage or thawing.                                      |
| when           | the product within a specified time after thawing. when                                                                                     |
| if             | A warning against further processing of the product if  there is evidence of breakage or thawing.                                           |
| as soon as     | room temperature after thawing and to begin administration as soon as possible but no more than 4 hours after                               |
| where          | to its donor, or to the specific recipient, where  applicable.                                                                              |
| when           | information about the species of the contaminating organism when the transfusion service has been able to identify                          |
| when           | information about the species of the contaminating organism when the transfusion service has been able to identify                          |
| if             | than 3 days old for all pretransfusion testing if the recipient has been pregnant or transfused within                                      |
| if             | (d) A provision that,  if the unit of donor's blood has not been                                                                            |
| when           | include, but are not limited to, the following when applicable: (1) Donor records: (i) Donor selection, including                           |
| where          | Donor selection, including medical interview and examination and where  applicable, informed consent.                                       |
| where          | postal address provided at the time of donation where the donor may be contacted within 8 weeks                                             |
| if             | (x) Records of not if ication of donors deferred or determined not to                                                                       |
| if             | (xi) Records of not if ication of the referring physician of a deferred                                                                     |
| if             | infection due to HIV, HBV, or HCV, and, if  applicable, HTLV or Chagas disease.                                                             |
| if             | can be readily determined to facilitate its recall, if  necessary.                                                                          |
| when           | or electronically transmitted mail as soon as possible. when                                                                                |
| as soon as     | telephone, facsimile, express mail, or electronically transmitted mail as soon as  possible.                                                |
| when           | transfusion service who had control over the product when  the deviation occurred, must report under this section.                          |
| if             | unlicensed blood or blood components, including Source Plasma, if that event meets all the following criteria: (1)                          |
| when           | (c) When do I report under this section? when                                                                                               |
| as soon as     | You should report a biological product deviation  as soon as possible but you must report at a date                                         |
| where          | (e) Where do I report under this section? where                                                                                             |
| if             | address in &#167;&#8201;600.2(a) of this chapter), and ident if y on the envelope that a BPDR (biological                                   |
| if             | address in &#167;&#8201;600.2(a) of this chapter), and ident if y on the envelope that a BPDR (biological                                   |


## Entities

| Entities         | Context                                                                                                                            |
|:-----------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                   |
| Equipment        | Equipment .                                                                                                                        |
| Such             | Such examination shall include inspection for breakage of seals,                                                                   |
| Research         | by the Director, Center for Biologics Evaluation and Research , are not applicable to establishments not subject                   |
| Plateletpheresis | Plateletpheresis , leukapheresis, and plasmapheresis.                                                                              |
| Plasma           | (5) For Whole Blood,  Plasma , Platelets, and partial units of Red Blood                                                           |
| Research         | by the Director, Center for Biologics Evaluation and Research  (CBER).                                                             |
| Remain           | machine-readable information can be scanned correctly; and (C) Remain  intact under normal conditions of use.                      |
| Contains         | blood intended for transfusion must be labeled: &#8220; Contains (name of antibody).&#8221; (2) Except for frozen, deglycerolized, |
| Contains         | product is intended for transfusion, the statement: &#8220; Contains (name of antibody).&#8221; (3) If tests for unexpected        |
| Contains         | product is intended for transfusion, the statement: &#8220; Contains (name of antibody).&#8221; (3) If tests for unexpected        |
| Products Subject | licensable products, the statement: &#8220;Not for Use in Products Subject to License Under Section 351 of the Public              |
| License          | statement: &#8220;Not for Use in Products Subject to License Under Section 351 of the Public Health Service                        |
| Careful          | Careful donor selection and available laboratory tests do not                                                                      |
| Plasma           | (m) For  Plasma , the circular of information must contain:                                                                        |
| Good             | (8) The statement: &#8220; Good patient management requires monitoring treatment responses to Cryoprecipitated                     |
| Laboratory       | Laboratory control procedures shall include: (a) The establishment of                                                              |
| Distribution     | Distribution  and receipt; procedures and records.                                                                                 |
| Adverse          | Adverse  reaction file.                                                                                                            |
| Research         | 3486 to the Center for Biologics Evaluation and Research  (CBER), either in paper or electronic format.                            |


